Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPIREN: Spironolactone in Kidney Transplant
NCT01602861Phase 4Completed
- Sponsor
- University Hospital Odense
- Start
- Feb 2013
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in nephrotoxicity comparing Spironolactone with Placebo (2 arms). Primary endpoint: Change in Chrome-EDTA Clearance at 3 years. Started Feb 2013; status: completed.
02
Drugs
spironolactone
03
Conditions
nephrotoxicity
Beyond the preview
Go deeper on NCT01602861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01602861.